
|Videos|October 1, 2021
Dr. Chughtai discusses novel iTind system for BPH treatment
Author(s)Urology Times staff
“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.
Advertisement
In this video, Bilal Chughtai, MD, assesses the success of the iTind system as reported in the study, “Preservation of ejaculatory and erectile function with iTind system for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association annual meeting. Chughtai is an associate professor of urology, obstetrics and gynecology at Weill Cornell Medicine and an attending urologist at NewYork-Presbyterian Hospital, New York City, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











